Cytokinetics (NASDAQ: CYTK) is a biopharmaceutical company focused on muscle biology. It develops treatments for diseases that involve muscle weakness and fatigue. A key product for Cytokinetics is MYQORZO, a drug designed to treat adults with a heart condition known as symptomatic obstructive hypertrophic cardiomyopathy (HCM). On May 5, 2026, Cytokinetics reported its first-quarter financial results. The company posted a loss of $1.67 per share, which met analyst expectations. As highlighted by Zacks, this ...